NCT02134964 is a Phase 1 clinical trial of OLT1177 Capsules in Healthy Volunteers, sponsored by Olatec Therapeutics LLC.

Who is sponsoring NCT02134964?

NCT02134964 is sponsored by Olatec Therapeutics LLC.

What drugs are being tested in NCT02134964?

Interventions in NCT02134964: OLT1177 Capsules, Placebo Capsules.

What condition does NCT02134964 study?

NCT02134964 studies Healthy Volunteers.

Is NCT02134964 still recruiting?

NCT02134964 is currently completed. Last updated 5 March 2015.

Last reviewed 2015-03-05 · How we verify

NCT02134964

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase 1, Randomized, Dose Escalation, Single Center, Safety and Pharmacokinetic Study of Single and Multi-Dose, Orally Administered OLT1177 Capsules in Healthy Subjects

Completed Phase 1 Last updated 5 March 2015

What this trial tests

Phase 1 trial testing OLT1177 Capsules in Healthy Volunteers in 35 participants. Completed in 1 December 2014.

Timeline

1 June 2014

Primary endpoint
1 December 2014

1 December 2014

Quick facts

Lead sponsor	Olatec Therapeutics LLC
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	single group
Masking	quadruple
Primary purpose	basic science
Enrollment	35
Start date	1 June 2014
Primary completion	1 December 2014
Estimated completion	1 December 2014
Sites	1 location across United States

Drugs / interventions tested

OLT1177 Capsules — full drug profile →
Placebo Capsules — full drug profile →

Conditions studied

Healthy Volunteers — all drugs for Healthy Volunteers →

Sponsor

Olatec Therapeutics LLC — full company profile →

Who can join

Adults 18 to 60, any sex, with Healthy Volunteers. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Recording of adverse events
Time frame: Screening through Day 28 follow-up
Adverse events will be described with respect to seriousness, intensity, relationship to treatment, action taken and outcome of the event.

Sponsor's own description

This study is a randomized, placebo-controlled, sequential ascending-dose study of healthy volunteers after administration of single or multiple dose(s) of investigational drug (OLT1177 Caps or Placebo Caps). A total of 36 subjects will be enrolled across 6 cohorts, and subjects in each cohort will be randomized in a ratio of 5 active to 1 placebo.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

The role of inflammasomes in human diseases and their potential as therapeutic targets.
Yao J, Sterling K, Wang Z, Zhang Y, et al · · 2024 · cited 135× · PMID 38177104 · DOI 10.1038/s41392-023-01687-y
Targeting pyroptosis in inflammatory bowel disease: A potentially effective therapeutic approach.
Dong WW, Liu T, He LX, He WT. · · 2025 · cited 1× · PMID 41358180 · DOI 10.3748/wjg.v31.i43.111358
The NLRP3 Inflammasome: Mechanisms of Activation, Regulation, and Therapeutic Opportunities.
Zou C, Jiang S, Li H, Zhao K, et al · · 2026 · PMID 41799937 · DOI 10.1002/mco2.70660

Verify or expand the search:

Other recruiting trials for Healthy Volunteers

Currently open trials in the same condition.

NCT07504003 — Influence of Training Session Duration on Improvements in Physiological Resilience to Exercise · NA · recruiting
NCT07446400 — A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuva · Phase 1 · recruiting
NCT07495813 — A Study to See How RO7763505 Works and How Safe it is When Given to Healthy People and People With Stable Heart Disease · Phase 1 · recruiting
NCT07499050 — A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity · Phase 1 · recruiting
NCT07342114 — A Dose-Escalation Study of RO7875913 in Healthy Participants · Phase 1 · recruiting

Other Olatec Therapeutics LLC trials

Trials by the same sponsor.

NCT05658575 — Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare · Phase 2, PHASE3 · recruiting
NCT04540120 — Safety and Efficacy of Dapansutrile for Treatment of Moderate COVID-19 Symptoms and Evidence of Early Cytokine Release S · Phase 2 · terminated
NCT03534297 — Study of Dapansutrile Capsules in Heart Failure · Phase 1 · completed
NCT03595371 — Pilot Study of Dapansutrile Capsules in Schnitzler's Syndrome · Phase 2 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02134964 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Olatec Therapeutics LLC
Last refreshed: 5 March 2015

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02134964.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing